Literature DB >> 6392348

Epithelial markers in prostatic, bladder, and colorectal cancer: an immunoperoxidase study of epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphatase.

E Heyderman, B M Brown, T C Richardson.   

Abstract

Twenty prostatic adenocarcinomas, 20 transitional cell carcinomas of the bladder, and 20 colorectal adenocarcinomas were stained for epithelial membrane antigen, carcinoembryonic antigen, and prostatic acid phosphatase. Polyclonal affinity purified first and second antibodies and an indirect immunoperoxidase technique were used. All of the colorectal and bladder tumours and 16/20 prostatic tumours were positive for epithelial membrane antigen. All 20 colorectal, 7/20 bladder, and 5/20 prostatic tumours stained for carcinoembryonic antigen. All of the prostatic adenocarcinomas and none of the colorectal or bladder tumours were positive for prostatic acid phosphatase. These markers may be used to discriminate between tumours arising from these sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6392348      PMCID: PMC499028          DOI: 10.1136/jcp.37.12.1363

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  35 in total

1.  Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens.

Authors:  D M Goldenberg; R M Sharkey; F J Primus
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

2.  A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue.

Authors:  E Heyderman; K Steele; M G Ormerod
Journal:  J Clin Pathol       Date:  1979-01       Impact factor: 3.411

3.  Prostatic acid phosphatase in tissue sections revealed by the unlabelled antibody peroxidase-antiperoxidase method.

Authors:  J Burns
Journal:  Biomedicine       Date:  1977-01-31

4.  Indirect immunofluorescence for identification of prostatic epithelial cells.

Authors:  J E Pontes; B Choe; N Rose; J M Pierce
Journal:  J Urol       Date:  1977-04       Impact factor: 7.450

5.  Identification of an antigen from normal human tissue that crossreacts with the carcinoembryonic antigen.

Authors:  S von Kleist; G Chavanel; P Burtin
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

6.  Acid phosphomonesterase of human prostate. Molecular weight, dissociation and chemical composition.

Authors:  M Derechin; W Ostrowski; M Galka; E A Barnard
Journal:  Biochim Biophys Acta       Date:  1971-10

7.  Immunohistological demonstration of prostatic origin of malignant neoplasms.

Authors:  M Nadji; Z Tabei; A Castro; A R Morales
Journal:  Lancet       Date:  1979-03-24       Impact factor: 79.321

8.  Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.

Authors:  D M Purnell; B M Heatfield; B F Trump
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

9.  Immunohistochemical diagnosis of prostatic cancer with metastasis.

Authors:  C Y Li; W K Lam; L T Yam
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

10.  Immunoperoxidase detection of carcinoembryonic antigen and blood group substances in papillary transitional cell carcinoma of the bladder.

Authors:  E L Wiley; G Mendelsohn; M J Droller; J C Eggleston
Journal:  J Urol       Date:  1982-08       Impact factor: 7.450

View more
  9 in total

1.  Cross reactivity of anti-epithelial membrane antigen monoclonal for reactive and neoplastic glial cells.

Authors:  E Hitchcock; C S Morris
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

2.  Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1.

Authors:  E Anagnostaki; D Skarlos; N Tamvakis; P Psaropoulou; E Blana; A Bamias; S Legaki; G Aravantinos; C Deliveliotis; K Dimopoulos
Journal:  Br J Cancer Suppl       Date:  1990-07

3.  Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2.

Authors:  E Heyderman; S E Larkin; P J O'Donnell; A M Haines; P J Warren; A Northeast; A G Grant
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

4.  Comparative study of carcinoembryonic antigen and epithelial membrane antigen expression in normal colon, adenomas and adenocarcinomas of the colon and rectum.

Authors:  B R Davidson; V R Sams; J Styles; C Dean; P B Boulos
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

5.  HMFG-2 as a prognostic indicator in superficial bladder cancer.

Authors:  I G Conn; J Crocker; L A Emtage; D M Wallace
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

6.  A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry.

Authors:  A M Haines; S E Larkin; A P Richardson; R W Stirling; E Heyderman
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

7.  Twenty-sixth annual general meeting of the British Association for Cancer Research (in conjunction with the European Organization for Research and Treatment for Cancer--Pharmacokinetics and Metabolism Group and the Drug Metabolism Group). March 24-27, 1985, Birmingham, U.K.

Authors: 
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

8.  Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer.

Authors:  Sarah R Ambrose; Naheema S Gordon; James C Goldsmith; Wenbin Wei; Maurice P Zeegers; Nicholas D James; Margaret A Knowles; Richard T Bryan; Douglas G Ward
Journal:  Proteomes       Date:  2015-09-03

9.  A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.

Authors:  E Heyderman; I Strudley; G Powell; T C Richardson; J L Cordell; D Y Mason
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.